- Details
- Jonathan Rosenberg joins Alicia Morgans to discuss the results of the BAYOU trial. BAYOU is a randomized phase II study examining durvalumab and olaparib as first-line therapy in platinum-ineligible patients with unresectable stage IV urothelial carcinoma. Biographies: Jonathan E. Rosenberg, MD, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; and the Enno W....
|
- Details
- Sam Chang hosts Yohann Loriot to discuss the LEAP-011 study. The study aims to evaluate the combination of pembrolizumab and lenvatinib for treating metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy. Despite promising preliminary data from the KEYNOTE-146 study, the LEAP-011 trial finds no significant difference in progression-free survival (PFS) or overall su...
|
- Details
- Alicia Morgans and Matthew Galsky discuss a two-part open-label study of trastuzumab deruxtecan with nivolumab in patients with HER2 expressing urothelial carcinoma. Dr. Galsky provides background on the rise of combination therapies of antibody-drug conjugates and immune checkpoint blockades in urothelial cancer. They also discuss the preliminary success of this combination therapy and that we wi...
|
- Details
- Ashish Kamat hosts Guru Sonpavde to discuss key findings from the GU ASCO symposium. Dr. Sonpavde reviews a range of groundbreaking studies, emphasizing the potential of systemic therapy for metastatic bladder cancer. Noteworthy trials include TROPHY-U-01, which shows a 34% response rate combining sacituzumab govitecan with pembrolizumab, and a study on neoadjuvant enfortumab vedotin revealing a 3...
|
- Details
- Dimitrios Makrakis joins Alicia Morgans and Petros Grivas in a discussion on a BJU International publication titled The Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer looking at a data set trying to understand the important potential interaction between exposure to checkpoint inhibitors and local therapy for patients at the time of diagnosis ass...
|
- Details
- Guru Sonpavde joins Ashish Kamat sharing takeaways from the 2021 ESMO meeting starting with practice-changing or practice reaffirming studies, followed by other emerging drugs and data. Dr. Sonpavde highlighted the landmark phase 3 EV-301 study that led to the approval of enfortumab vedotin in post-platinum and PD-1 inhibitor-treated patients with metastatic urothelial carcinoma. Among the other s...
|
- Details
- In this conversation with Alicia Morgans, Matthew Galsky highlights an exploratory analysis within the IMvigor130 randomized phase III study of patients with metastatic urothelial cancer who were treatment-naive. IMvigor130 was asking two separate questions, should we combine platinum-based chemotherapy with atezolizumab versus giving platinum-based chemotherapy alone, and should we give immune ch...
|
- Details
- Ashish Kamat, MD, MBBS, and Bishoy Faltas, MD, discuss immuno-oncology approaches across the spectrum of urothelial carcinoma. They discuss chemotherapy coupled with immune checkpoint inhibitors and how the combination may benefit patients with urothelial cancers. Further, they discuss the JAVELIN Bladder 100 trial, a randomized 700 patient trial that evaluated maintenance avelumab treatment. Biog...
|
- Details
- In this UroToday discussion between Petros Grivas, MD, PhD, Guru Sonpavde, MD, and Maria Carlo, MD, the trio discuss recent publications on germline testing and genetic profiling. The conversation kicks off with a background on Dr. Carlo’s recent work concerning genetic testing for urothelial and bladder cancer patients. The conversation shifts to hear from Dr. Sonpavde about his recent work in lo...
|
- Details
- In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...
|